אפרקס 6000 ישראל - עברית - Ministry of Health

אפרקס 6000

j-c health care ltd - erythropoietin human recombinant - תמיסה להזרקה - erythropoietin human recombinant 6000 iu / 0.6 ml - erythropoietin - erythropoietin - treatment of severe anemia associated with chronic renal failure, anemia in zidovudine treated hiv infected patients, anemia in cancer patients on chemotherapy.to increase the yield of autologous blood from patients in a predonation programme initiated to avoid the use of homologous blood. treatment is indicated in patients with moderate anemia (packed cell volume (pcv) approximately 33 to 39% , no iron deficiency) if blood conserving procedures are not available or insufficient either: a: when the scheduled major elective surgery requires a large volume of blood ( 4 or more units of blood for females or 5 or more units for males) or b: when the period necessary to obtain the required volume of autologous blood is too short. perisurgery: reduction of allogeneic blood transfusion in surgery patients : eprex is indicated for the treatment of anemic patients (hemoglobin 9-11 g/dl) scheduled to undergo elective, noncardiac, nonvascular surgery to reduce the need for allogeneic blood transfusions. eprex is indicat

אפרקס 8000 ישראל - עברית - Ministry of Health

אפרקס 8000

j-c health care ltd - erythropoietin human recombinant - תמיסה להזרקה - erythropoietin human recombinant 8000 iu / 0.8 ml - erythropoietin - erythropoietin - treatment of severe anemia associated with chronic renal failure, anemia in zidovudine treated hiv infected patients, anemia in cancer patients on chemotherapy.to increase the yield of autologous blood from patients in a predonation programme initiated to avoid the use of homologous blood. treatment is indicated in patients with moderate anemia (packed cell volume (pcv) approximately 33 to 39% , no iron deficiency) if blood conserving procedures are not available or insufficient either: a: when the scheduled major elective surgery requires a large volume of blood ( 4 or more units of blood for females or 5 or more units for males) or b: when the period necessary to obtain the required volume of autologous blood is too short. perisurgery: reduction of allogeneic blood transfusion in surgery patients : eprex is indicated for the treatment of anemic patients (hemoglobin 9-11 g/dl) scheduled to undergo elective, noncardiac, nonvascular surgery to reduce the need for allogeneic blood transfusions. eprex is indicat

אפרקס 40000 ישראל - עברית - Ministry of Health

אפרקס 40000

j-c health care ltd - erythropoietin human recombinant - תמיסה להזרקה - erythropoietin human recombinant 40000 iu/ml - erythropoietin - erythropoietin - treatment of severe anemia associated with chronic renal failure, anemia in zidovudine treated hiv infected patients, anemia in cancer patients on chemotherapy.to increase the yield of autologous blood from patients in a predonation programme initiated to avoid the use of homologous blood. treatment is indicated in patients with moderate anemia (packed cell volume (pcv) approximately 33 to 39% , no iron deficiency) if blood conserving procedures are not available or insufficient either: a: when the scheduled major elective surgery requires a large volume of blood ( 4 or more units of blood for females or 5 or more units for males) or b: when the period necessary to obtain the required volume of autologous blood is too short. perisurgery: reduction of allogeneic blood transfusion in surgery patients : eprex is indicated for the treatment of anemic patients (hemoglobin 9-11 g/dl) scheduled to undergo elective, noncardiac, nonvascular surgery to reduce the need for allogeneic blood transfusions. eprex is indicat

רקורמון 30000 IU ישראל - עברית - Ministry of Health

רקורמון 30000 iu

roche pharmaceuticals (israel) ltd - epoetin beta - תמיסה להזרקה - epoetin beta 30000 iu / 0.6 ml - erythropoietin - erythropoietin - treatment of anemia associated with chronic renal failure (renal anemia) in patients on dialysis. treatment of symptomatic renal anemia in patients not yet undergoing dialysis. increasing the yield of autologous blood from patients in a pre-donation program. its use in this indication must be balanced against the reported increased risk of thromboembolic events. treatment should only be given to patients with moderate anemia (hb 10-13 g/dl (6.21- 8.07 mmol/l) no iron deficiency) or when blood conserving procedures are not available or insufficient when the scheduled major elective surgery requires a large volume of blood (4 or more units of blood for females or 5 or more units for males). treatment of anemia in adult patients with solid tumors and treated with chemotherapy . treatment of anemia in adult patients with multiple myeloma low grade non-hodgkin's lymphoma or chronic lymphocytic leukemia who have a relative erythropoietin deficiency and are receiving anti-tumor therapy. deficiency is defined as an i

אפרקס 20000 ישראל - עברית - Ministry of Health

אפרקס 20000

j-c health care ltd - erythropoietin human recombinant - תמיסה להזרקה - erythropoietin human recombinant 20000 iu / 0.5 ml - erythropoietin - erythropoietin - treatment of severe anemia associated with chronic renal failure, anemia in zidovudine treated hiv infected patients, anemia in cancer patients on chemotherapy.to increase the yield of autologous blood from patients in a predonation programme initiated to avoid the use of homologous blood. treatment is indicated in patients with moderate anemia (packed cell volume (pcv) approximately 33 to 39% , no iron deficiency) if blood conserving procedures are not available or insufficient either: a: when the scheduled major elective surgery requires a large volume of blood ( 4 or more units of blood for females or 5 or more units for males) or b: when the period necessary to obtain the required volume of autologous blood is too short. perisurgery: reduction of allogeneic blood transfusion in surgery patients : eprex is indicated for the treatment of anemic patients (hemoglobin 9-11 g/dl) scheduled to undergo elective, noncardiac, nonvascular surgery to reduce the need for allogeneic blood transfusions. eprex is indicat

אפרקס 30000 ישראל - עברית - Ministry of Health

אפרקס 30000

j-c health care ltd - erythropoietin human recombinant - תמיסה להזרקה - erythropoietin human recombinant 30000 iu / 0.75 ml - erythropoietin - erythropoietin - treatment of severe anemia associated with chronic renal failure, anemia in zidovudine treated hiv infected patients, anemia in cancer patients on chemotherapy.to increase the yield of autologous blood from patients in a predonation programme initiated to avoid the use of homologous blood. treatment is indicated in patients with moderate anemia (packed cell volume (pcv) approximately 33 to 39% , no iron deficiency) if blood conserving procedures are not available or insufficient either: a: when the scheduled major elective surgery requires a large volume of blood ( 4 or more units of blood for females or 5 or more units for males) orb: when the period necessary to obtain the required volume of autologous blood is too short. perisurgery: reduction of allogeneic blood transfusion in surgery patients : eprex is indicated for the treatment of anemic patients (hemoglobin 9-11 g/dl) scheduled to undergo elective, noncardiac, nonvascular surgery to reduce the need for allogeneic blood transfusions. eprex is indicate

פרגניל 5000 יח' בינל ישראל - עברית - Ministry of Health

פרגניל 5000 יח' בינל

merck sharp & dohme israel ltd - human chorionic gonadotropin - אבקה להכנת תמיסה לזריקה - human chorionic gonadotropin 5000 iu/ml - chorionic gonadotrophin - chorionic gonadotrophin - in the female: ovulation induction in infertility due to anovulation or impaired follicle-ripening. preparation of follicles for puncture in controlled ovarian hyperstimulation programs. luteal phase support. in the male: hypogonadotropic hypogonadism (also cases of idiopathic dysspermias have shown a positive response to gonadotropins). delayed puberty associated with insufficient gonadotropic pituitary function.cryptorchidism not due to anatomical obstruction.

פוסטימון 75 IU ישראל - עברית - Ministry of Health

פוסטימון 75 iu

tzamal bio-pharma ltd - urofollitropin - אבקה להכנת תמיסה לזריקה - urofollitropin 75 iu/vial - urofollitropin - urofollitropin - a treatment with fsh followed by the administration of human chronic gonadotrophin (hcg) is indicated to induce ovulation in infertile women suffering from hypothalamus or hypophyseal disorders and in spanomenorrhoeic or amenorrhoeic women. these women belong to the who group ii and have generally already been treated with clomiphene citrate. most have polycystic ovarian syndrome. fsh offers good therapeutic prospects for patients whose lh:fsh ratio has to be adjusted, avoiding an exogenous supply of lh fsh may be used alone or in concomitance with human menopausal gonadotropin (hmg) in order to stimulate multiple follicular growth in patients involved in medically assisted reproduction programs (ivf-et,gift).

פוסטימון 150 IU ישראל - עברית - Ministry of Health

פוסטימון 150 iu

tzamal bio-pharma ltd - urofollitropin - אבקה להכנת תמיסה לזריקה - urofollitropin 150 iu/vial - urofollitropin - urofollitropin - a treatment with fsh followed by the administration of human chronic gonadotrophin (hcg) is indicated to induce ovulation in infertile women suffering from hypothalamus or hypophyseal disorders and in spanomenorrhoeic or amenorrhoeic women. these women belong to the who group ii and have generally already been treated with clomiphene citrate. most have polycystic ovarian syndrome. fsh offers good therapeutic prospects for patients whose lh:fsh ratio has to be adjusted, avoiding an exogenous supply of lh fsh may be used alone or in concomitance with human menopausal gonadotropin (hmg) in order to stimulate multiple follicular growth in patients involved in medically assisted reproduction programs (ivf-et,gift).

פיורגון תמיסה להזרקה ישראל - עברית - Ministry of Health

פיורגון תמיסה להזרקה

organon pharma israel ltd., israel - follitropin beta - תמיסה להזרקה - follitropin beta 833 iu / 1 ml - follitropin beta - follitropin beta - puregon is indicated for the treatment of female infertility in the following clinical situations: anovulation (including polycystic ovarian disease, pcod) in women who have beenunresponsive to treatment with clomiphene citrate. controlled ovarian hyperstimulation to induce the development of multiple follicles in medically assisted reproduction programs [ e.g. in vitro fertilisation/embryo transfer (ivf/et), gamete intra-fallopian transfer (gift) and intracytoplasmic sperm injection (icsi)]. in the male : deficient spermatogenesis due to hypogonadotrophic hypogonadism.